| MAU | multi-attribute utility [model] |
|---|---|
| MAUT | multi-attribute utility theory |
| MESCH | Multi-Environment Scheme |
| MHP | hemiplegic migraine; maternal health program; maternal health program; medical center health plan; 1... |
| MIAs | multi-institutional arrangements; medically indigent adults |
| iron-storage disease | The storage of excess iron in the parenchyma of many organs, as in idiopathic haemochromatosis or transfusion haemosiderosis. (05 Mar 2000) |
|---|---|
| iron-storage protein | <chemical> Soluble iron storage protein from e coli; different from ferritin and haemosiderin (05 Dec 1998) |
| iron succinyl milk protein complex | <chemical> Soluble iron complex with 5% iron content produced by reacting succinylated milk protein and ferric chloride Synonym: iron succinyl protein complex, itf 282, itf-282 (05 Dec 1998) |
| iron sulfate | A soluble iron salt frequently used as an iron supplement in tablets and liquid preparations. Synonym: ferrous sulfate. (05 Mar 2000) |
| iron-sulfur proteins | A group of proteins possessing only the iron-sulfur complex as the prosthetic group. These proteins participate in all major pathways of electron transport: photosynthesis, respiration, hydroxylation and bacterial hydrogen and nitrogen fixation. (12 Dec 1998) |
| total iron binding capacity | <biochemistry, haematology> A test that measures indirectly the transferrin level in the bloodstream. Transferrin is a protein that carries iron in the body. Normal values are 240 to 450 mcg/dl. This test is used to evaluate anaemia. Greater than normal total iron binding capacity can be seen in: iron deficiency anaemia, late pregnancy and polycythaemia vera. Lower than normal total iron binding capacity can be seen in cirrhosis, sickle cell anaemia, hypoproteinaemia, pernicious anaemia and haemolytic anaemia. The use of birth control pills can lead to increased total iron binding capacity measurements. Acronym: TIBC (12 Jan 1998) |
| ferric citrate iron reductase | <enzyme> Requires fmn, uses NADH; fre1 and fre2 provide membrane-associated ferric reductase activity for saccharomyces cerevisiae Registry number: EC 1.6.99.- Synonym: ferric iron reductase, iron reductase, ferric reductase, NADH-dependent, ferrireductase, iron (iii) reductase, ferric reductase, fre1 gene product, fre2 gene product, ferric-chelate reductase, NADH-dependent ferric-chelate reductase, NADH-dependent iron(iii)-chelate reductase, fecitr, NADH-fe(iii)-chelate reductase, nfr enzyme (26 Jun 1999) |
| Lillie's ferrous iron stain | <technique> A method using potassium ferrocyanide in acetic acid which demonstrates melanins as a deep green colour; lipofuscins and haem pigments are unreactive. (05 Mar 2000) |
| administration, oral | The giving of drugs, chemicals, or other substances by mouth. (12 Dec 1998) |
| cancer, oral | Cancer of the mouth area. A sore in the mouth that does not heal can be a warning sign of oral cancer. A biopsy is the only to know whether as abnormal area in the oral cavity is cancer. Oral cancer is caused by tobacco (smoking and chewing) and alcohol use. Surgery to remove the tumour in the mouth is the usual treatment for patients with oral cancer. (12 Dec 1998) |
| candidiasis, oral | Infection of the mucous membranes of the mouth by a fungus of the genus candida. (12 Dec 1998) |
| canine oral papilloma | Warts affecting mucous membranes of young dogs; caused by a papillomavirus. (05 Mar 2000) |
| magnesia and alumina oral suspension | A mixture of magnesium hydroxide and variable amounts of aluminum oxide; used as an antacid. (05 Mar 2000) |
| pathology, oral | A dental specialty concerned with pathology of the oral cavity. (12 Dec 1998) |
| pharyngo-oral | Relating to the pharynx and the mouth; oropharyngeal. Origin: pharyngo-+ L. Os (or-), mouth (05 Mar 2000) |